Telix Advances Brain Cancer Imaging with FDA NDA Acceptance
Telix Pharmaceuticals Limited (ASX: TLX), a global biopharmaceutical company, has achieved a key regulatory milestone with the U.S. FDA accepting its resubmitted New Drug Application for TLX101-Px (Pixclara®), a PET imaging agent designed to detect glioma (brain cancer). The application has been assigned a target decision date of September 11, 2026. This imaging solution aims to address a critical gap in distinguishing tumor progression from treatment-related changes, a major challenge in glioma management.
TLX101-Px has received Orphan Drug and Fast Track designations, highlighting its potential clinical importance. The product is also aligned with international imaging guidelines and could support treatment decisions, including use alongside Telix’s therapeutic candidate TLX101-Tx. Headquartered in Australia, Telix focuses on radiopharmaceutical development for oncology and rare diseases, with a growing global presence. The company continues to advance its pipeline to improve diagnostic precision and patient outcomes in complex cancers.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Telix Advances Brain Cancer Imaging with FDA NDA Acceptance
Telix Pharmaceuticals Limited (ASX: TLX), a global biopharmaceutical company, has achieved a key regulatory milestone with the U.S. FDA accepting its resubmitted New Drug Application for TLX101-Px (Pixclara®), a PET imaging agent designed to detect glioma (brain cancer). The application has been assigned a target decision date of September 11, 2026. This imaging solution aims to address a critical gap in distinguishing tumor progression from treatment-related changes, a major challenge in glioma management.
TLX101-Px has received Orphan Drug and Fast Track designations, highlighting its potential clinical importance. The product is also aligned with international imaging guidelines and could support treatment decisions, including use alongside Telix’s therapeutic candidate TLX101-Tx. Headquartered in Australia, Telix focuses on radiopharmaceutical development for oncology and rare diseases, with a growing global presence. The company continues to advance its pipeline to improve diagnostic precision and patient outcomes in complex cancers.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au